Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Macquarie Technology Day 2011
23 slides from Fisher & Paykel Healthcare's conference presentation, Oct 20, 2011
Slide 1: Improving Care & Outcomes
Improving Care & Outcomes Macquarie Technology Day, 20 October 2011 1 Improving Care & Outcomes • The Care Continuum - Matthew Payton • F&P Optiflow - Matthew Payton • F&P Info Technologies - Lewis Gradon • ICON with SensAwake – Emma Duckworth 2
Slide 2: OSA Compliance Monitoring
OSA Compliance Monitoring • Galetke W et al. Respiration 82(2): 155-61: (2011) – 303 patients, Median follow-up was 13 months (range 7-18 months) – 63% still used the PAP device regularly – 27.4% had definitively discontinued PAP treatment – 9.5% discontinued PAP treatment within the first 3 months
Slide 3: F&P Info Technologies
F&P Info Technologies™ 5 F&P Info Technologies • Advanced patient management system compatible with all F&P CPAP devices • Computer or web-based application • Data reporting available: – Compliance from first use (cumulative) – Usage and efficacy data for up to 365 days – Detailed efficacy data (7 n
Slide 4: Patient Devices Patient Reports Patient Prescriptions Patient Contacts
Patient Devices Patient Reports Patient Prescriptions Patient Contacts ig InfoSmart”,, <0: Full Patient Report Joba Smit | 07 octz014 PATIENT DETAILS i | Names Tohn Sri Tender water ‘Addeaeet Test st Testcity Test County Patient 10: Date ofan: 18-hn-c2 Worl one: oossaszes Nome Phone: DEVICE DETAILS
Slide 5: InfoSmart Patient Report
[ED tatosmart Coont gig) InfoSmart™ .:: Patient Reports Patient Prescription: Patient Contacts Full Patient Report Joba Smith | 07 042014 Compliance Statistics Progress overa 20:day period: FromSatup Date 7 Start Date- End Date: 2mos2m0- 27042m9 ——_25/03/2010- 2504/2010 “Total DaysDevie Used 27 ds)
Slide 6: F&P Info Technologies Summary
F&P Info Technologies Summary • Designed to simplify data transfer and monitoring to keep business efficient and profitable • Provide flexible data solutions 11 12
Slide 7: ICON
ICON™ The F&P ICON includes: • ThermoSmart™ Technology for more humidity and comfort • Contemporary, stylish design for bedroom appeal • Forward facing clock with customizable AlarmTunes™ • Compact footprint including humidifier and power supply • Info Technologies™ for flexible data communication o
Slide 8: Benefits of SensAwake
Benefits of SensAwake SensAwake Lowest Waking Pressure • SensAwake pressure relief promptly reduces the pressure to the lowest most comfortable level as the patient wakes with the aim of: – Removing pressure awareness – Reducing conscious waking – Accelerating the return to sleep Removing pressure a
Slide 9: How does SensAwake Work?
Benefits of SensAwake Automatic Ramp • Ramp is routinely activated by patients to enhance comfort by lowering pressure • SensAwake automatically lowers the pressure upon sensing patient wakening • Its responsiveness lets the patient comfortably transition back to sleep 17 How does SensAwake Work? Ho
Slide 10: How does SensAwake Work?
How does SensAwake Work? Airflow Signal on the PSG • Regular breathing pattern during relaxed sleep • Irregular breathing during transition from sleep to awake • Irregularity during REM breathing does not display the same traits as the irregularity during awake breathing 19 How does SensAwake Work?
Slide 11: SensAwake Efficacy
How does SensAwake Work? SensAwake in Premo 21 SensAwake Efficacy Clinical Studies have shown • SensAwake™ accurately detects the transition from sleep to wake using the flow signal alone1 • AutoCPAP devices with SensAwake™ treat OSA as effectively and at a lower overall mean pressure than a traditi
Slide 12: SensAwake Efficacy: Proven to Treat
SensAwake Efficacy Proven to Treat • Delivering more awake comfort does not compromise therapy efficacy • Despite the fact that pressures are lower than conventional therapy, the efficacy of the devices has been shown1-3 • Both Auto and Premo2 devices have been validated in a clinical trials and AHI
Slide 13: The Care Continuum
The Care Continuum MORE CRITICAL LESS CRITICAL 25 The Care Continuum Hospital 26
Slide 14: Higher Flows of Air/Oxygen Delivered Comfortably
Higher Flows of Air/Oxygen Delivered Comfortably The combination of optimal humidity with nasal cannula enables comfortable delivery of high flows • Without Optimal Humidity – Tolerating high flows delivered directly into the nares would be impossible – Significant drying of the upper airway can occ
Slide 15: Optiflow: AIRVO / MyAirvo
Optiflow: AIRVO / MyAirvo 29 Delivering Optiflow F&P Optiflow Nasal Cannula • Wide bore cannulae designed to deliver high flows without gas jetting • Ergonomically designed for exceptional comfort around the nasal septum • Lightweight and flexible • Mobile condensate is reduced by the unique breatha
Slide 16: Optiflow Benefits
Optiflow Benefits • Clinical benefits better outcomes – Fewer escalations of therapy – Shorter hospital stay – Lower costs 31 Optiflow Benefits Level 3 Clinical Outcomes Level 2 Physiological Outcomes Level 1 Mechanisms of Action 32
Slide 17: Mechanisms of Action
Mechanisms of Action 1. Comfort 2. Deliver up to 100% oxygen accurately 3. Flushing of anatomical deadspace 4. Positive airway pressure during the respiratory cycle 5. Optimised mucociliary clearance 33 Mechanisms of Action: Comfort Comfortable, effective oxygen delivery • Roca et al, Respiratory Ca
Slide 18: Mechanisms of Action: Accuracy
Mechanisms of Action: Accuracy • With Nasal High Flow we aim to meet the patient’s inspiratory demand with flow • This enables the delivery of a set FiO2, even when a patients respiratory mechanics change 35 Mechanisms of Action: Accuracy • When compared to face mask oxygen therapy, Sim et al demons
Slide 19: Mechanisms of Action: Flushing of Anatomical Deadspace
Mechanisms of Action: Flushing of Anatomical Deadspace • Continuous flushing of the upper airway (anatomical deadspace) • Washout is caused by the continuous delivery of high flows 37 Mechanisms of Action: Flushing of Anatomical Deadspace There are two key benefits of this flushing effect: • Reduces
Slide 20: Mechanisms of Action: Positive Airway Pressure
Mechanisms of Action: Positive Airway Pressure • Parke et al compared nasopharyngeal airway pressures with NHF and face mask oxygen therapy with mouth open and mouth closed Adapted from Parke et al, 2008 39 Mechanisms of Action: Mucociliary Clearance • Hasani et al used a radio-aerosol technique to
Slide 21: Physiological and Clinical Outcomes
Physiological Outcomes • Roca et al (Acute respiratory failure) found: – Less dyspnoea – Improved oxygenation – Reduced respiratory rate – No change in PaCO2 • Corley et al, Prince Charles Hospital, Critical Care Research Group, Queensland (using EIT on 20 post operative cardiac surgical patients) f
Slide 22: Clinical Outcomes: Exacerbations
Clinical Outcomes: Exacerbations • Rea et al 2010, Respiratory Medicine • 108 patients diagnosed with COPD or bronchiectasis • Daily humidification therapy 12 months • Usual care for 12months • Measured outcomes: – Exacerbation rates – Lung function spirometry – quality of life – exercise capacity e
Slide 23: Patient Profiles
Patient Profiles Categories Conditions Symptoms Airway disease Bronchitis Obstructed airways limit airflow and Asthma ventilation. Secretion quantity and Emphysema quality leads to mucus plugging and obstruction Diffuse lung disease Pulmonary Fibrosis Reduced lung compliance and lung Pneumoconiosis
Fisher & Paykel Healthcare — Macquarie Technology Day 2011 on 6ix